Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nuvo Research, a specialty pharmaceutical company, has launched Synera (70mg lidocaine/ 70mg tetracaine/ heated topical patch) in the US.
Subscribe to our email newsletter
Synera is approved for use on intact skin to provide local dermal analgesia for superficial venous access and superficial dermatological procedures such as excision, electrodessication and shave biopsy of skin lesions.
This new sales force will initially target a highly concentrated number of doctors and clinics that perform these painful procedures as a regular part of their practice.
Nuvo pain group president Bradley Galer said Synera has great potential and now represents their second source of revenue, in addition to Pennsaid.
"Also, by the end of 2012, we expect EU and US approval and the launch of our third commercial product, Pliaglis, by our worldwide marketing partner, Galderma Pharma," Galer added.